No Data
No Data
Elevance Health's Growth Potential Justifies Buy Rating Amid Sector Challenges
Buy Rating for Elevance Health: Stable Medicaid and Medicare Advantage Outlook With Potential Upside
Deutsche Bank Cuts Elevance Health Price Target to $463 From $465, Maintains Buy Rating
RBC Capital Reiterates Outperform on Elevance Health, Maintains $478 Price Target
Jefferies Adjusts Price Target on Elevance Health to $488 From $461, Maintains Buy Rating
Express News | Guggenheim Reiterates Buy on Elevance Health, Maintains $518 Price Target